PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩1,400 per share · Prices as of the 2026-10-02 close
Chong Kun Dang Holdings has seen operating profit turn from loss to a steadily improving profit on the back of subsidiary earnings gains, but large-scale capital spending and reliance on short-term borrowing have emerged as a new financial burden.
Consolidated operating profit reached KRW 58.28 billion in 2025 with a 6.1% margin, extending four straight years of improvement since the 2022 operating loss.
Q2 2026 operating profit dropped sharply to KRW 6.64 billion quarter-on-quarter, while owners' net income rose to KRW 16.85 billion, a diverging pattern.
The introduction of Wegovy by Chong Kun Dang boosted combined group revenue, but rising reliance on in-licensed products also increased cost-of-goods pressure.
Nearly trillion-won-scale CAPEX including the Siheung Baegot bio R&D complex and Kyungbo Pharm's ADC CDMO plant is expected to push up combined net debt/EBITDA.
Chairman Lee Jang-han's plan to gift his 9.55% stake in Chong Kun Dang to his three children is set to begin in late September 2026, continuing the third-generation succession process.
Chong Kun Dang Holdings was launched in 2013 through a spin-off from Chong Kun Dang, and it operates as a pure holding company whose main income sources are brand licensing fees, management advisory fees, and dividend income.
Under the Fair Trade Act it holds nine subsidiaries, including Chong Kun Dang, Kyungbo Pharm, Chong Kun Dang Bio, Chong Kun Dang Health, and Chong Kun Dang Industry, spanning pharmaceuticals, API and finished drugs, health functional food, and real estate.
As of the first quarter of 2026, revenue composition was led by Chong Kun Dang Health at 48%, Kyungbo Pharm at 26%, Chong Kun Dang Bio at 16%, the holding company itself at 6%, and Chong Kun Dang Industry at 5%, meaning health functional food and API businesses account for more than half of group revenue.
Chong Kun Dang Holdings owns a 43.41% stake in the listed subsidiary Kyungbo Pharm and has been steadily increasing its stake in Chong Kun Dang every year since 2023.
The group's core revenue driver, Chong Kun Dang, sells both its own developed drugs and in-licensed products such as Wegovy (an obesity treatment from Novo Nordisk), Godex, and Pecsulu in the domestic prescription drug market.
Kyungbo Pharm, which started as an API manufacturer, has recently diversified into antibody-drug conjugate (ADC) CDMO business, while Chong Kun Dang Bio is building fermentation-based probiotics raw material supply and microbiome CDMO capabilities.
The largest shareholder is Chairman Lee Jang-han, who holds a 33.73% stake in Chong Kun Dang Holdings, and a third-generation succession centered on his eldest son is proceeding through equity gifts at subsidiaries.
As one of Korea's major pharmaceutical group holding structures, it diversifies single-business pharmaceutical risk through its portfolio of subsidiaries.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩242.2B | ₩16.5B | 6.8% |
| 2025Q3 | ₩234.2B | ₩18.1B | 7.7% |
| 2025Q4 | ₩236B | ₩11.8B | 5.0% |
| 2026Q1 | ₩240.3B | ₩19.3B | 8.0% |
| 2026Q2 | ₩251.2B | ₩6.6B | 2.6% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩909B | -₩32.9B | ₩1.1B | −3.6% | 0.2% | 72.4% |
| 2023 | ₩879.8B | ₩17B | ₩47B | 1.9% | 8.4% | 76.8% |
| 2024 | ₩957.8B | ₩35.5B | ₩33.6B | 3.7% | 5.7% | 76.0% |
| 2025 | ₩959B | ₩58.3B | ₩40.4B | 6.1% | 6.3% | 78.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-22
Consolidated revenue at Chong Kun Dang Holdings fell from KRW 909.0 billion in 2022 to KRW 879.8 billion in 2023, then recovered to KRW 957.8 billion in 2024 and KRW 959.0 billion in 2025, holding in the KRW 900 billion range for three straight years.
Operating profit improved every year, moving from a loss of KRW 32.88 billion in 2022 to KRW 17.01 billion in 2023, KRW 35.49 billion in 2024, and KRW 58.28 billion in 2025, with the operating margin climbing steadily from -3.6% to 1.9%, 3.7%, and 6.1%.
Net income attributable to owners was just KRW 1.07 billion in 2022 before jumping to KRW 47.01 billion in 2023, then KRW 33.60 billion in 2024 and KRW 40.43 billion in 2025.
Operating cash flow also improved markedly, from negative KRW 46.50 billion in 2022 to KRW 37.15 billion in 2023, KRW 24.48 billion in 2024, and KRW 76.04 billion in 2025, underpinning a recovery in cash generation.
On a quarterly basis, owners' net income was KRW 13.40 billion in Q3 2025, eased to KRW 10.53 billion in Q4 2025, then rose again to KRW 12.89 billion in Q1 2026 and KRW 16.85 billion in Q2 2026.
However, operating profit fell sharply from KRW 19.28 billion in Q1 2026 to KRW 6.64 billion in Q2 2026, diverging from the rise in owners' net income, suggesting non-operating factors such as equity-method gains, foreign exchange, or one-off items may have offset weaker core profitability.
By subsidiary, Chong Kun Dang's revenue grew on the back of Wegovy sales, though its operating margin actually narrowed as the share of in-licensed products increased cost ratios, while Kyungbo Pharm's operating profit improved on higher API and finished-drug sales.
The debt ratio rose gradually from 72.4% in 2022 to 78.4% in 2025, indicating leverage expanded modestly alongside the earnings recovery.
In Korea's prescription drug market, competition is intensifying around the domestic distribution of global drugs such as the obesity treatment Wegovy and Eylea, amid a growing share of in-licensed products.
Although Chong Kun Dang is counted among the top five pharmaceutical companies, its operating margin is relatively low; on a consolidated basis in 2025, its margin trailed Hanmi Pharmaceutical (16.66%), Daewoong Pharmaceutical (12.53%), and Yuhan Corporation (4.77%), while staying above GC Biopharma (3.47%).
The health functional food market is in a phase of stagnant growth amid intensifying competition, and Chong Kun Dang Health's profitability has been shaky due to advertising and home-shopping commission costs despite growth in new-product sales.
In the API and CDMO space, demand for contract development and manufacturing is rising alongside expansion of antibody-drug conjugate (ADC) therapeutics, with Kyungbo Pharm and Chong Kun Dang Bio each expanding facility investment in ADC and microbiome/probiotics respectively to pursue new growth engines.
Across the group, combined holding-and-subsidiary revenue reached KRW 688.0 billion in Q1 2026, up 6.2% year-on-year, with the combined operating margin improving to 4.8%, confirming the effect of business diversification.
Still, across the pharma and bio sector broadly, rising R&D and capital expenditure burdens mean revenue growth does not automatically translate into profit growth, a structural characteristic evident in recent results.
Chong Kun Dang plans to build a bio-pharmaceutical R&D complex in the Siheung Baegot district by 2028, with an additional KRW 392.5 billion earmarked for constructing research and pilot facilities on top of already-spent land acquisition costs.
Kyungbo Pharm is building an ADC CDMO plant worth roughly KRW 85.5 billion, while Chong Kun Dang Bio is investing about KRW 45–46 billion in its Ansan plant to expand CDMO capacity.
To meet these funding needs, Chong Kun Dang Holdings issued KRW 60 billion (with room to upsize to KRW 100 billion) in public bonds in July 2026, with part of the proceeds earmarked for further equity purchases in subsidiaries including Chong Kun Dang.
Credit rating agencies assigned an A+ (stable) rating to the bonds, but forecast that combined net debt/EBITDA across the group could rise to around 2.5x in 2026–2027 due to the heavy capital expenditure needs.
On the governance front, a plan for Chairman Lee Jang-han to gift his entire 1,318,807-share (9.55%) stake in Chong Kun Dang to his three children is scheduled to proceed from September 30 to October 29, 2026, marking a further step in third-generation succession.
Chong Kun Dang also faces a Ministry of Health and Welfare review for 'innovative pharmaceutical company' certification and a Ministry of Food and Drug Safety efficacy review of Gliatilin in the second half of 2026, outcomes that could affect future earnings and drug pricing.
As a pure holding company, Chong Kun Dang Holdings has tended to trade at a discount relative to the value of its subsidiary stakes, and its share price has also formed in a range representing a meaningful discount to net asset value.
Owners' net income moved from near-loss territory in 2022 to a clear recovery through 2025, and the earnings base underlying valuation has continued to hold up over the most recent four quarters.
Dividends have been paid consistently every year, and despite recent earnings improvement, the dividend policy has remained on a relatively stable footing.
That said, the large capital expenditure program and growing reliance on short-term borrowing are variables that could affect net asset value and future earnings, and should be weighed together when assessing equity value.
Given that the multiple has moved within a range established over recent years, it is worth examining the pace of earnings improvement at each subsidiary alongside changes in financial burden rather than drawing an absolute conclusion.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-22
The operating margin improved markedly from -3.6% in 2022 to 6.1% in 2025, and operating cash flow swung from negative KRW 46.50 billion to positive KRW 76.04 billion over the same period. Simultaneous earnings improvement across subsidiaries has broadened the group's overall profit base. Owners' net income also maintained a rising quarterly trend through the first half of 2026.
Kyungbo Pharm is building an ADC CDMO plant worth about KRW 85.5 billion, while Chong Kun Dang Bio is investing in its Ansan plant and expanding probiotics/microbiome CDMO capacity.
These subsidiaries are proactively positioning for growing industry demand for contract development and manufacturing, a factor supporting medium-to-long-term portfolio diversification. Chong Kun Dang Holdings is also strengthening its control over these new businesses through equity investment.
Bonds issued by Chong Kun Dang Holdings received an A+ (stable) rating from domestic credit rating agencies. On a standalone basis, its debt ratio stood at 21.3% and net-debt dependency at 6.4%, keeping the holding company's own balance sheet relatively conservative. Dividend income and brand licensing fees from subsidiaries continue to serve as a stable source of cash inflow.
Nearly trillion-won-scale CAPEX, including the Siheung Baegot research complex and an ADC CDMO plant, is expected to push combined net debt/EBITDA to around 2.5x in 2026–2027. Observers also note that a high proportion of short-term borrowing within total debt exposes the group to refinancing risk. The debt ratio has also risen gradually from 72.4% in 2022 to 78.4% in 2025.
Expanded sales of in-licensed products such as Wegovy, Godex, and Pecsulu have driven Chong Kun Dang's revenue growth, but rising cost ratios have instead pushed the operating margin lower.
In Q2 2026, group consolidated operating profit fell sharply to KRW 6.64 billion from the prior quarter, illustrating quarterly volatility. Revenue growth with a low proportion of proprietary new drugs is cited as a factor that can lower the quality of earnings.
Chong Kun Dang Health accounts for nearly half of group revenue, but revenue growth has slowed amid intensifying competition in the health functional food market. There have also been periods of profitability strain from rising advertising costs and home-shopping commissions tied to new product launches. The pace of recovery in this segment has a relatively large impact on overall group results.
The group's structure of funding large CAPEX substantially through short-term borrowing continues, leaving refinancing risk in place. Rating agencies have noted that combined net debt/EBITDA exceeding 3.5x could become a factor for a credit rating downgrade.
If a high interest rate environment persists, financing costs could offset a substantial portion of operating profit gains.
Amid Chairman Lee Jang-han's advancing age, third-generation succession is proceeding in stages via equity gifts at subsidiaries, but the method and timing of transferring his 33.73% holding-company stake have not yet been finalized.
Depending on whether the succession proceeds via equity swaps or in-kind contributions, structural changes could occur that affect minority shareholder value. If earnings weakness persists at subsidiaries such as Kyungbo Pharm that could serve as succession levers, the succession timeline itself could also be affected.
Chong Kun Dang faces a Ministry of Health and Welfare 'innovative pharmaceutical company' certification review and a Ministry of Food and Drug Safety efficacy review of Gliatilin in the second half of 2026, outcomes that could directly affect future revenue and drug pricing policy.
As reliance on in-licensed products grows, changes in supply contract terms or cost ratios have a greater impact on results. The health functional food segment may also be exposed to regulatory and certification issues.
Chairman Lee Jang-han's plan to gift his entire 9.55% Chong Kun Dang stake to his three children is set to proceed, offering a concrete gauge of third-generation succession progress.
Chong Kun Dang Holdings' preliminary Q3 2026 earnings disclosure is due, warranting a check on whether the Wegovy-driven revenue effect persists and how the operating margin trend evolves.
This is Kyungbo Pharm's stated target for the first-phase startup of its ADC CDMO plant, warranting a check on whether the plan proceeds on schedule and early utilization indicators.
Results of the Ministry of Health and Welfare's 'innovative pharmaceutical company' certification review and the Ministry of Food and Drug Safety's Gliatilin efficacy review are due, and their potential impact on Chong Kun Dang's earnings and drug pricing should be monitored.
Chong Kun Dang Holdings is a holding company that has recovered from an operating loss in 2022 to an operating profit of KRW 58.28 billion and a 6.1% margin in 2025, with subsidiary earnings improvement clearly reflected in the results.
However, quarterly profit trends have diverged somewhat in 2026, with operating profit plunging from KRW 19.28 billion in Q1 to KRW 6.64 billion in Q2, even as owners' net income rose from KRW 12.89 billion to KRW 16.85 billion, highlighting a gap between core and non-operating earnings.
On the growth side, the pharmaceutical segment's expansion via Wegovy and ongoing ADC/CDMO investment at Kyungbo Pharm and Chong Kun Dang Bio are notable, but the associated large-scale CAPEX and reliance on short-term borrowing are flagged as financial burdens.
On governance, third-generation succession is proceeding through equity gifts at subsidiaries amid Chairman Lee Jang-han's advancing age, with a Chong Kun Dang stake gift scheduled from late September 2026, warranting close attention to ownership structure changes.
Intensifying competition in health functional food and a margin structure centered on in-licensed drugs are additional variables to weigh when assessing earnings quality.
This report does not offer an investment opinion or target price, and readers are encouraged to form their own judgment based on the bullish and bearish factors and checkpoints presented above.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.